The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 49 | — | 20.1x | Near average | |
Growth | 18 | — | 5.6% | Below average | |
Quality | 11 | -89.2% | 7.6% | Below average | |
Safety | 46 | 0.7x | 0.4x | Near average | |
Capital Return | 31 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Vera Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Vera Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The VERA stock witnessed a 9.16% decline in the average target price over the past 30 days, as the consensus dropped from 76.4 to 69.4 dollars despite the number of analysts remaining constant. This downward adjustment reflects a reassessment of the expected price range, with a sharp Dispersion between the low of 33 dollars and the ambitious high of 91 dollars, indicating uncertainty regarding the timeline for achieving clinical value.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.